Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 22 (Search time: 0.003 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Yeung, D.
;
Osborn, M.
;
White, D.
;
Branford, S.
;
Haswell, L.
;
Slader, C.
;
Issa, S.
;
Hiwase, D.
;
Hertzberg, M.
;
Schwarer, A.
;
Filshie, R.
;
Arthur, C.
;
Kwan, Y.
;
Forsyth, C.
;
Ross, D.
;
Mills, A.
;
Grigg, A.
;
Hughes, T.
;
Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
Branford, S.
;
Goh, H.
;
Izzo, B.
;
Beppu, L.
;
Ortmann, C.
;
Duniec, K.
;
Jin, Y.
;
Woodman, R.
;
Pane, F.
;
Kim, D.
;
Radich, J.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistance
Parker, W.
;
Ho, M.
;
Lawrence, R.
;
Irwin, D.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Towards DNA-based monitoring of therapy in chronic myeloid leukemia
Morley, A.
;
Bartley, P.
;
Ross, D.
;
Latham, S.
;
Budgen, B.
;
Branford, S.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
Contrasting response of patients with chronic myeloid leukaemia (CML) and the highly imatinib resistant L248V mutation that may be related to an increased propensity of some patients to form an associated deletion mutant with increased imatinib sensitivity
Prime, H.
;
Romeo, G.
;
Phillis, S.
;
Field, C.
;
Jamison, B.
;
Prime, J.
;
Parker, W.
;
Joske, D.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010
Limiting the variability within a BCR-ABL quantitative PCR (RQ-PCR) assay is essential for optimal concordance of results between laboratories generating BCR-ABL values on an international reporting scale
Fletcher, L.
;
Prime, J.
;
Phillis, S.
;
Jamison, B.
;
Field, C.
;
Prime, H.
;
Sullivan, B.
;
Yeoman, A.
;
Georgievski, J.
;
Parker, W.
;
Slader, C.
;
Hughes, T.
;
Branford, S.
;
Haematology Association of Australasia Annual Meeting (2010 : Auckland, New Zealand)
2010
Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy
Hiwase, D.
;
White, D.
;
Zrim, S.
;
Saunders, V.
;
Vaz de Melo, J.
;
Hughes, T.
2010
Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity
Engler, J.
;
Frede, A.
;
Saunders, V.
;
Zannettino, A.
;
Hughes, T.
;
White, D.
2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
Ross, D.
;
Branford, S.
;
Seymour, J.
;
Schwarer, A.
;
Arthur, C.
;
Bartley, P.
;
Slader, C.
;
Field, C.
;
Dang, P.
;
Filshie, R.
;
Mills, A.
;
Grigg, A.
;
Vaz de Melo, J.
;
Hughes, T.
Discover
Author
13
Branford, S.
7
White, D.
5
Saunders, V.
4
American Society of Hematology Me...
4
Frede, A.
4
Kim, D.
4
Radich, J.
4
Ross, D.
4
Zannettino, A.
3
Bartley, P.
.
next >
Subject
11
Humans
10
Pyrimidines
8
Benzamides
8
Imatinib Mesylate
8
Piperazines
7
Leukemia, Myelogenous, Chronic, B...
6
Antineoplastic Agents
6
Protein Kinase Inhibitors
5
Female
5
Male
.
next >